I remember when Glaxo Wellcome hooked up with SmithKline Beecham nearly seven years ago. Then again, that's also the last thing that I remember about GlaxoSmithKline (NYSE:GSK), as I'm not usually the one writing about the major pharmaceutical companies.

So I've invited Brian Lawler and Ryan Fuhrmann -- fresh from butting heads last month on Eli Lilly (NYSE:LLY) and tackling both sides of Pfizer (NYSE:PFE) back in February -- to come share the pro and con arguments for owning a piece of GlaxoSmithKline.

Man, that name is a mouthful. Now let's see if the bullish Brian and the bearish Ryan can give you an earful of the investing implications of GlaxoSmithKline.

Where do you stand on this high-yielding Income Investor recommendation? Read on and decide for yourself.

Duel on!

Glaxo and Eli Lilly are Income Investor picks. Pfizer is a Motley Fool Inside Value recommendation.

Longtime Fool contributor Rick Munarriz does not own shares in any of the companies in this story. The Fool has a disclosure policy.